DiaSorin's immunodiagnostics segment is a core area of expertise, focusing on the development and manufacturing of reagent kits used to detect antibodies and antigens. This segment leverages technologies like chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) to provide accurate and reliable diagnostic results. The therapeutic areas covered include infectious diseases, autoimmune disorders, and endocrinology. R&D efforts are directed towards expanding the menu of available tests, improving assay sensitivity and specificity, and automating workflows for increased efficiency. The segment's market positioning is strengthened by its established LIAISON platform, which offers a broad range of tests and high throughput capabilities. Future opportunities lie in expanding into emerging markets and developing novel assays for unmet clinical needs.

The molecular diagnostics segment at DiaSorin focuses on developing and commercializing tests based on nucleic acid amplification techniques, such as polymerase chain reaction (PCR). This segment is crucial for the detection and quantification of viral and bacterial pathogens, as well as for genetic testing and personalized medicine applications. R&D activities are centered on developing new assays with improved sensitivity, specificity, and multiplexing capabilities. The LIAISON MDX platform is a key technology in this segment, offering automated sample processing and real-time PCR analysis. The therapeutic areas covered include infectious diseases, oncology, and inherited disorders. The segment's market positioning is enhanced by its ability to provide rapid and accurate diagnostic results, enabling timely clinical decision-making. Future growth opportunities include expanding into point-of-care testing and developing companion diagnostics for targeted therapies.

DiaSorin's Licensed Technologies Group (LTG), stemming from the Luminex acquisition, focuses on providing innovative multiplexing solutions for research and diagnostic applications. This segment develops and licenses its xMAP technology, which enables the simultaneous detection of multiple analytes in a single reaction. R&D efforts are directed towards expanding the capabilities of the xMAP platform, developing new assays, and supporting the needs of its licensing partners. The therapeutic areas covered include infectious diseases, immunology, and genetics. The segment's market positioning is strengthened by its established customer base and its ability to provide flexible and customizable solutions. Future opportunities lie in expanding into new markets and developing novel applications for the xMAP technology.